 Connection
Andrey Soares to Carcinoma, Transitional Cell
This is a "connection" page, showing publications Andrey Soares has written about Carcinoma, Transitional Cell.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.010 |
|
|
|
-
Soares A, Bourlon MT, Wong A, Joshi A, Jardim D, Korbenfeld E, Karak FE, Orlandi F, Sze H, Ansari J, Zarba J, Mansour MA, Manneh R, Thirumulai R, Tsai YC, Morsi WA, Powles T. Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion. Clin Genitourin Cancer. 2024 04; 22(2):467-475.
Score: 0.818
-
Rizzo A, Zayed A, Vitale E, Buti S, Takeshita H, Crabb S, Roviello G, Seront E, Tapia JC, Scagliarini S, Popovic L, Kopp RM, Abahssain H, Rizzo M, Monteiro FSM, Massafra R, Brunetti O, Santini D, Ürün Y, Montironi R, Mollica V, Massari F, Soares A, Santoni M. Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset. Clin Exp Metastasis. 2025 Sep 06; 42(5):52.
Score: 0.230
-
Rizzo M, Soares A, Gupta S, Calabrò F, Takeshita H, Bourlon MT, Park SH, Giannatempo P, Myint ZW, Büttner T, Grande E, Fiala O, Santini D, Bamias A, Zakopoulou R, Buti S, Kanesvaran R, Rescigno P, Molina-Cerrillo J, Epstein I, Marques Monteiro FS, Massari F, Porta C, Bellmunt J, Santoni M. Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study. JCO Glob Oncol. 2025 Jul; 11:e2400564.
Score: 0.227
-
Rizzo M, Morelli F, Ürün Y, Buti S, Park SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, Takeshita H, Roviello G, Myint ZW, Popovic L, Soares A, Abahssain H, Giannatempo P, Molina-Cerrillo J, Incorvaia L, Salah S, Zeppellini A, Monteiro FSM, Porta C, Gupta S, Santoni M. Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience. Cancer Med. 2025 Feb; 14(4):e70479.
Score: 0.220
-
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bisonni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N, Buti S, Porta C, Bellmunt J. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. Cancer Immunol Immunother. 2024 Apr 18; 73(6):106.
Score: 0.209
-
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Cattrini C, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchenhorn D, Santini D, Manneh R, Bisonni R, Zakopoulou R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Sorgentoni G, Battelli N, Porta C, Bellmunt J, Santoni M. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. Cancer Immunol Immunother. 2023 Nov; 72(11):3665-3682.
Score: 0.200
-
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study. Target Oncol. 2024 Nov; 19(6):905-915.
Score: 0.054
-
Rizzo M, Soares A, Grande E, Bamias A, Kopp RM, Lenci E, Buttner T, Salah S, Grillone F, de Carvalho IT, Tapia JC, Gucciardino C, Pinto A, Mennitto A, Abahssain H, Rescigno P, Myint Z, Takeshita H, Spinelli GP, Popovic L, Vitale MG, Fiala O, Giannatempo P, Zakopoulou R, Carrozza F, Massari F, Monteiro FSM, Pace MP, Giannini M, Roviello G, Porta C, Battelli N, Kanesvaran R, Santoni M. Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study. Sci Rep. 2024 08 27; 14(1):19802.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|